Evidence map›Paper›PMID 33075069›Full record

ArticlePLoS neglected tropical diseases2020

Quorum sensing N-Acyl homoserine lactones are a new class of anti-schistosomal.

Helen Whiteland, Alessandra Crusco, Lisa W Bloemberg, Jamie Tibble-Howlings, Josephine Forde-Thomas, Avril Coghlan, Patrick J Murphy, Karl F Hoffmann

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Small Molecule Ligands of the BET-like Bromodomain,Journal of medicinal chemistry · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Helen WhitelandInstitute of Biological, Environmental and Rural Sciences (IBERS), Aberystwyth University, Aberystwyth, Wales, United Kingdom.ORCID 0000-0002-2650-5977
Alessandra CruscoInstitute of Biological, Environmental and Rural Sciences (IBERS), Aberystwyth University, Aberystwyth, Wales, United Kingdom.
Lisa W BloembergInstitute of Biological, Environmental and Rural Sciences (IBERS), Aberystwyth University, Aberystwyth, Wales, United Kingdom.ORCID 0000-0002-9749-0207
Jamie Tibble-HowlingsSchool of Natural Sciences, Bangor University, Gwynedd, United Kingdom.
Josephine Forde-ThomasInstitute of Biological, Environmental and Rural Sciences (IBERS), Aberystwyth University, Aberystwyth, Wales, United Kingdom.ORCID 0000-0002-7202-3565
Avril CoghlanWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.ORCID 0000-0002-2775-5951
Patrick J MurphySchool of Natural Sciences, Bangor University, Gwynedd, United Kingdom.
Karl F HoffmannInstitute of Biological, Environmental and Rural Sciences (IBERS), Aberystwyth University, Aberystwyth, Wales, United Kingdom.ORCID 0000-0002-3932-5502
Aberystwyth University · GBBangor University · GBWellcome Sanger Institute · GB

Funding

Wellcome TrustWellcome Trust 201008/Z/16/Z
6 · The paper itself

Abstract

backgroundSchistosomiasis is a prevalent neglected tropical disease that affects approximately 300 million people worldwide. Its treatment is through a single class chemotherapy, praziquantel. Concerns surrounding the emergence of praziquantel insensitivity have led to a need for developing novel anthelmintics. METHODOLOGY/PRINCIPLE

findingsThrough evaluating and screening fourteen compounds (initially developed for anti-cancer and anti-viral projects) against Schistosoma mansoni, one of three species responsible for most cases of human schistosomiasis, a racemic N-acyl homoserine (1) demonstrated good efficacy against all intra mammalian lifecycle stages including schistosomula (EC50 = 4.7 μM), juvenile worms (EC50 = 4.3 μM) and adult worms (EC50 = 8.3 μM). To begin exploring structural activity relationships, a further 8 analogues of this compound were generated, including individual (R)- and (S)- enantiomers. Upon anti-schistosomal screening of these analogues, the (R)- enantiomer retained activity, whereas the (S)- lost activity. Furthermore, modification of the lactone ring to a thiolactone ring (3) improved potency against schistosomula (EC50 = 2.1 μM), juvenile worms (EC50 = 0.5 μM) and adult worms (EC50 = 4.8 μM). As the effective racemic parent compound is structurally similar to quorum sensing signaling peptides used by bacteria, further evaluation of its effect (along with its stereoisomers and the thiolactone analogues) against Gram+ (Staphylococcus aureus) and Gram- (Escherichia coli) species was conducted. While some activity was observed against both Gram+ and Gram- bacteria species for the racemic compound 1 (MIC 125 mg/L), the (R) stereoisomer had better activity (125 mg/L) than the (S) (>125mg/L). However, the greatest antimicrobial activity (MIC 31.25 mg/L against S. aureus) was observed for the thiolactone containing analogue (3). CONCLUSION/SIGNIFICANCE: To the best of our knowledge, this is the first demonstration that N-Acyl homoserines exhibit anthelmintic activities. Furthermore, their additional action on Gram+ bacteria opens a new avenue for exploring these molecules more broadly as part of future anti-infective initiatives.

Indexed as

Quorum SensingAcyl-ButyrolactonesAnimalsAnthelminticsAnti-Infective AgentsEscherichia coliHep G2 CellsHumansMiceMicrobial Sensitivity TestsNeglected DiseasesSchistosoma mansoniSchistosomiasis mansoniStaphylococcus aureusStructure-Activity RelationshipAcyl-ButyrolactonesAnthelminticsAnti-Infective Agents

Identifiers

PMID33075069
PMCPMC7595621
OpenAlexW3092663542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.